Cargando…
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock
INTRODUCTION: Tumor necrosis factor-alpha (TNF-α), an early mediator in the systemic inflammatory response to infection, is a potential therapeutic target in sepsis. The primary objective of this study was to determine the safety and tolerability of AZD9773, an ovine, polyclonal, anti-human TNF-α Fa...
Autores principales: | Morris, Peter E, Zeno, Brian, Bernard, Andrew C, Huang, Xiangning, Das, Shampa, Edeki, Timi, Simonson, Steven G, Bernard, Gordon R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3396277/ https://www.ncbi.nlm.nih.gov/pubmed/22340283 http://dx.doi.org/10.1186/cc11203 |
Ejemplares similares
-
Safety and tolerability of an ovine-derived polyclonal anti-TNFα Fab fragment (AZD9773) in patients with severe sepsis
por: Morris, P, et al.
Publicado: (2011) -
AZD9773 is a novel and potent anti-TNFα polyclonal ovine immune Fab
por: Newham, P, et al.
Publicado: (2011) -
Preclinical pharmacodynamics and safety profiling of AZD9773: a novel anti-TNFα polyclonal immune ovine Fab similar to D-CytoFab
por: Newham, P, et al.
Publicado: (2011) -
Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects
por: Das, Shampa, et al.
Publicado: (2015) -
AZD9773, a novel anti-TNFα immune Fab in development for severe sepsis and septic shock: demonstration of safety and efficacy in a murine CLP sepsis model
por: Newham, P, et al.
Publicado: (2011)